Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK plus NSCLC in the phase II ALTA trial

D. H. Lee; D-W. Kim; D. R. Camidge; C. J. Langer; R. M. Huber; M. Tiseo; H. L. West; H. J. M. Groen; K. L. Reckamp; M. J. Hochmair; N. B. Leighl; K. H. Hansen; S. N. Gettinger; L. Paz-Ares; E. S. Kim; E. F. Smit; S-W. Kim; Q. Ni; P. Zhang; M-J. Ahn

Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK plus NSCLC in the phase II ALTA trial

D. H. Lee, D-W. Kim, D. R. Camidge, C. J. Langer, R. M. Huber, M. Tiseo, H. L. West, H. J. M. Groen, K. L. Reckamp, M. J. Hochmair, N. B. Leighl, K. H. Hansen, S. N. Gettinger, L. Paz-Ares, E. S. Kim, E. F. Smit, S-W. Kim, Q. Ni, P. Zhang, M-J. Ahn

Onderzoeksoutput › Academic

Originele taal-2	English
Pagina's (van-tot)	634-635
Aantal pagina's	2
Tijdschrift	Annals of Oncology
Volume	30
Status	Published - okt.-2019
Evenement	44th Congress of the European-Society-for-Medical-Oncology (ESMO) - Barcelona, Spain Duur: 27-sep.-2019 → 1-okt.-2019

Handle.net

Permanente koppeling

Citeer dit

Lee, D. H., Kim, D-W., Camidge, D. R., Langer, C. J., Huber, R. M., Tiseo, M., West, H. L., Groen, H. J. M., Reckamp, K. L., Hochmair, M. J., Leighl, N. B., Hansen, K. H., Gettinger, S. N., Paz-Ares, L., Kim, E. S., Smit, E. F., Kim, S-W., Ni, Q., Zhang, P., & Ahn, M-J. (2019). Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK plus NSCLC in the phase II ALTA trial. Annals of Oncology, 30, 634-635.

@article{7bda043557a044b1aa2ec83360d7b260,

title = "Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK plus NSCLC in the phase II ALTA trial",

author = "Lee, {D. H.} and D-W. Kim and Camidge, {D. R.} and Langer, {C. J.} and Huber, {R. M.} and M. Tiseo and West, {H. L.} and Groen, {H. J. M.} and Reckamp, {K. L.} and Hochmair, {M. J.} and Leighl, {N. B.} and Hansen, {K. H.} and Gettinger, {S. N.} and L. Paz-Ares and Kim, {E. S.} and Smit, {E. F.} and S-W. Kim and Q. Ni and P. Zhang and M-J. Ahn",

year = "2019",

month = oct,

language = "English",

volume = "30",

pages = "634--635",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

note = "44th Congress of the European-Society-for-Medical-Oncology (ESMO) ; Conference date: 27-09-2019 Through 01-10-2019",

}

Lee, DH, Kim, D-W, Camidge, DR, Langer, CJ, Huber, RM, Tiseo, M, West, HL, Groen, HJM, Reckamp, KL, Hochmair, MJ, Leighl, NB, Hansen, KH, Gettinger, SN, Paz-Ares, L, Kim, ES, Smit, EF, Kim, S-W, Ni, Q, Zhang, P & Ahn, M-J 2019, 'Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK plus NSCLC in the phase II ALTA trial', Annals of Oncology, vol. 30, blz. 634-635.

TY - JOUR

T1 - Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK plus NSCLC in the phase II ALTA trial

AU - Lee, D. H.

AU - Kim, D-W.

AU - Camidge, D. R.

AU - Langer, C. J.

AU - Huber, R. M.

AU - Tiseo, M.

AU - West, H. L.

AU - Groen, H. J. M.

AU - Reckamp, K. L.

AU - Hochmair, M. J.

AU - Leighl, N. B.

AU - Hansen, K. H.

AU - Gettinger, S. N.

AU - Paz-Ares, L.

AU - Kim, E. S.

AU - Smit, E. F.

AU - Kim, S-W.

AU - Ni, Q.

AU - Zhang, P.

AU - Ahn, M-J.

PY - 2019/10

Y1 - 2019/10

M3 - Meeting Abstract

VL - 30

SP - 634

EP - 635

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

T2 - 44th Congress of the European-Society-for-Medical-Oncology (ESMO)

Y2 - 27 September 2019 through 1 October 2019

ER -